86 related articles for article (PubMed ID: 19857518)
1. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks.
Röskam S; Neff F; Schwarting R; Bacher M; Dodel R
Neurosci Biobehav Rev; 2010 Mar; 34(4):487-99. PubMed ID: 19857518
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
Schenk D
Nat Rev Neurosci; 2002 Oct; 3(10):824-8. PubMed ID: 12360327
[No Abstract] [Full Text] [Related]
4. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging.
Jensen MT; Mottin MD; Cracchiolo JR; Leighty RE; Arendash GW
Neuroscience; 2005; 130(3):667-84. PubMed ID: 15590151
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
[TBL] [Abstract][Full Text] [Related]
6. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage.
Burbach GJ; Vlachos A; Ghebremedhin E; Del Turco D; Coomaraswamy J; Staufenbiel M; Jucker M; Deller T
Neurobiol Aging; 2007 Feb; 28(2):202-12. PubMed ID: 16427722
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of Alzheimer disease: A beta vaccine].
Tabira T; Hara H
Rinsho Shinkeigaku; 2004 Nov; 44(11):778-80. PubMed ID: 15651289
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
Vasilevko V; Cribbs DH
Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
[TBL] [Abstract][Full Text] [Related]
9. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice.
Morgan D
Neurochem Int; 2006 Jul; 49(2):190-4. PubMed ID: 16740342
[TBL] [Abstract][Full Text] [Related]
10. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease.
Filali M; Lalonde R
Brain Res; 2009 Oct; 1292():93-9. PubMed ID: 19643098
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta immunotherapies in mice and men.
Brendza RP; Holtzman DM
Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
[TBL] [Abstract][Full Text] [Related]
12. Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation.
Heikkinen T; Kalesnykas G; Rissanen A; Tapiola T; Iivonen S; Wang J; Chaudhuri J; Tanila H; Miettinen R; Puoliväli J
Exp Neurol; 2004 May; 187(1):105-17. PubMed ID: 15081593
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.
Luo F; Rustay NR; Seifert T; Roesner B; Hradil V; Hillen H; Ebert U; Severin JM; Cox BF; Llano DA; Day M; Fox GB
J Pharmacol Exp Ther; 2010 Dec; 335(3):580-8. PubMed ID: 20823195
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice.
Tong XK; Nicolakakis N; Fernandes P; Ongali B; Brouillette J; Quirion R; Hamel E
Neurobiol Dis; 2009 Sep; 35(3):406-14. PubMed ID: 19524673
[TBL] [Abstract][Full Text] [Related]
15. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
Foster JK; Verdile G; Bates KA; Martins RN
Mol Psychiatry; 2009 Mar; 14(3):239-51. PubMed ID: 18957942
[TBL] [Abstract][Full Text] [Related]
16. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
Bard F; Cannon C; Barbour R; Burke RL; Games D; Grajeda H; Guido T; Hu K; Huang J; Johnson-Wood K; Khan K; Kholodenko D; Lee M; Lieberburg I; Motter R; Nguyen M; Soriano F; Vasquez N; Weiss K; Welch B; Seubert P; Schenk D; Yednock T
Nat Med; 2000 Aug; 6(8):916-9. PubMed ID: 10932230
[TBL] [Abstract][Full Text] [Related]
17. Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice.
Hanna A; Horne P; Yager D; Eckman C; Eckman E; Janus C
Genes Brain Behav; 2009 Oct; 8(7):676-84. PubMed ID: 19531156
[TBL] [Abstract][Full Text] [Related]
18. Learning and memory in transgenic mice modeling Alzheimer's disease.
Ashe KH
Learn Mem; 2001; 8(6):301-8. PubMed ID: 11773429
[TBL] [Abstract][Full Text] [Related]
19. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.
Lee KW; Lee SH; Kim H; Song JS; Yang SD; Paik SG; Han PL
J Neurosci Res; 2004 May; 76(4):572-80. PubMed ID: 15114629
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice.
Dewachter I; Filipkowski RK; Priller C; Ris L; Neyton J; Croes S; Terwel D; Gysemans M; Devijver H; Borghgraef P; Godaux E; Kaczmarek L; Herms J; Van Leuven F
Neurobiol Aging; 2009 Feb; 30(2):241-56. PubMed ID: 17673336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
